Livforsakringsbolaget Skandia Omsesidigt Lowered By $540,000 Its Cls’a’usd0.0000225 (ACN) Holding; 5 Analysts Bullish OncoMed Pharmaceuticals, Inc. (OMED)

February 17, 2018 - By Louis Casey

Livforsakringsbolaget Skandia Omsesidigt decreased Cls’a’usd0.0000225 (ACN) stake by 25.31% reported in 2017Q3 SEC filing. Livforsakringsbolaget Skandia Omsesidigt sold 4,000 shares as Cls’a’usd0.0000225 (ACN)’s stock declined 0.21%. The Livforsakringsbolaget Skandia Omsesidigt holds 11,802 shares with $1.59 million value, down from 15,802 last quarter. Cls’a’usd0.0000225 now has $100.31 billion valuation. The stock increased 0.99% or $1.6 during the last trading session, reaching $162.66. About 2.00M shares traded. Accenture plc (NYSE:ACN) has risen 4.27% since February 17, 2017 and is uptrending. It has underperformed by 12.43% the S&P500.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) earned “Buy” rating by Jefferies on Wednesday, September 9. BMO Capital Markets initiated the shares of OMED in report on Tuesday, April 12 with “Outperform” rating. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) earned “Buy” rating by SunTrust on Tuesday, December 20. BMO Capital Markets downgraded it to “Market Perform” rating and $6 target in Tuesday, April 11 report. The company was initiated on Friday, December 4 by Wells Fargo. The stock has “Buy” rating by Cantor Fitzgerald on Monday, April 18. Leerink Swann downgraded the stock to “Mkt Perform” rating in Monday, January 25 report. SunTrust maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Friday, October 6. SunTrust has “Hold” rating and $4.0 target. The firm has “Buy” rating by Jefferies given on Tuesday, September 26. Jefferies maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Thursday, August 24. Jefferies has “Buy” rating and $5.0 target. See OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) latest ratings:

06/10/2017 Broker: SunTrust Rating: Hold New Target: $4.0 Maintain
26/09/2017 Broker: Jefferies Rating: Buy New Target: $5.0 Maintain
19/09/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $6.0
24/08/2017 Broker: Jefferies Rating: Buy New Target: $5.0 Maintain

Livforsakringsbolaget Skandia Omsesidigt increased Ross Stores Inc (NASDAQ:ROST) stake by 40,600 shares to 59,480 valued at $3.84M in 2017Q3. It also upped Cvs Health Corp (NYSE:CVS) stake by 21,600 shares and now owns 66,059 shares. Com Stk Usd0.01 (NYSE:WSM) was raised too.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.05, from 1.05 in 2017Q2. It dived, as 40 investors sold ACN shares while 370 reduced holdings. 97 funds opened positions while 315 raised stakes. 461.53 million shares or 1.06% less from 466.45 million shares in 2017Q2 were reported. Meeder Asset Mgmt Incorporated reported 0.53% of its portfolio in Accenture plc (NYSE:ACN). Lincoln Natl Corporation invested in 1,690 shares or 0.01% of the stock. 400,001 were reported by Congress Asset Mngmt Ma. Midas Management Corporation holds 1.42% or 20,000 shares in its portfolio. Parkside Fincl Bank Trust reported 1,030 shares or 0.05% of all its holdings. Comml Bank stated it has 30,599 shares. Ameriprise Finance reported 0.1% in Accenture plc (NYSE:ACN). National Asset Mngmt stated it has 0.18% in Accenture plc (NYSE:ACN). Independent Franchise Prtn Ltd Liability Partnership accumulated 6.29 million shares. Csu Producer Res holds 12.79% in Accenture plc (NYSE:ACN) or 20,000 shares. Wetherby Asset Mngmt stated it has 0.44% of its portfolio in Accenture plc (NYSE:ACN). New York-based Qs Limited Com has invested 0.02% in Accenture plc (NYSE:ACN). Markel has invested 0.43% of its portfolio in Accenture plc (NYSE:ACN). 49,187 were accumulated by First Bancorp. Welch Group Inc Limited Liability Company owns 1,154 shares.

Among 26 analysts covering Accenture Plc (NYSE:ACN), 15 have Buy rating, 1 Sell and 10 Hold. Therefore 58% are positive. Accenture Plc had 89 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Goldman Sachs with “Sell” on Friday, June 23. As per Thursday, December 21, the company rating was maintained by Stifel Nicolaus. Barclays Capital maintained Accenture plc (NYSE:ACN) rating on Thursday, December 22. Barclays Capital has “Equal Weight” rating and $124 target. Berenberg initiated the shares of ACN in report on Thursday, October 13 with “Buy” rating. BMO Capital Markets maintained the shares of ACN in report on Friday, September 29 with “Market Perform” rating. Cantor Fitzgerald maintained Accenture plc (NYSE:ACN) rating on Monday, October 3. Cantor Fitzgerald has “Buy” rating and $139 target. As per Monday, March 27, the company rating was maintained by Credit Suisse. Morgan Stanley maintained the stock with “Hold” rating in Friday, June 16 report. The rating was maintained by Wells Fargo on Friday, September 29 with “Outperform”. The rating was maintained by KeyBanc Capital Markets on Monday, November 20 with “Overweight”.

The stock increased 7.14% or $0.15 during the last trading session, reaching $2.25. About 146,476 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since February 17, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

Since October 10, 2017, it had 0 insider purchases, and 5 insider sales for $27,111 activity. Shares for $5,295 were sold by Patel Sunil on Tuesday, October 10. 1,398 shares were sold by HASTINGS PAUL J, worth $5,931. Gurney Austin also sold $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, October 10. 1,248 shares were sold by Lewicki John A., worth $5,295. 1,248 shares valued at $5,295 were sold by Hager Alicia J. on Tuesday, October 10.

Investors sentiment increased to 0.71 in 2017 Q3. Its up 0.12, from 0.59 in 2017Q2. It is positive, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported. Tower Capital Lc (Trc) stated it has 5,250 shares or 0% of all its holdings. Hodges Mgmt Incorporated stated it has 0.01% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). 152,885 are held by Bank Of America Corp De. Schwab Charles Inv Management owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 50,729 shares. Axa owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 101,779 shares. State Bank Of Mellon Corp holds 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 23,538 shares. Nj State Employees Deferred Compensation Plan holds 38,000 shares. Connor Clark Lunn Invest Mgmt Ltd holds 69,900 shares. Fny Managed Accounts Limited Liability Corp accumulated 0.02% or 3,200 shares. State Street Corp holds 13,100 shares. Moreover, Glenmede Tru Na has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Moreover, Bridgeway Mgmt has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 88,900 shares. Royal National Bank & Trust Of Canada accumulated 14 shares. Northern Tru Corp has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Perceptive Advisors Ltd Liability Company accumulated 1.04 million shares.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $85.18 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Louis Casey

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: